IDEAYA Biosciences(DE:30J)
€28.37+0.15 (+5.54%)
DE:30J
IDEAYA Biosciences financials statements
€28.37
At close:+0.15 (+5.54%)
IDEAYA Biosciences (30J) Ratios
4 Followers
IDEAYA Biosciences Ratios
DE:30J's free cash flow for Q3 2026 was $-93.75M. For the 2026 fiscal year, DE:30J's free cash flow was decreased by $-273.00K and operating cash flow was $-93.48M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 |
| Quick Ratio | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 |
| Cash Ratio | 1.92 | 1.83 | 5.79 | 2.16 | 2.04 |
| Solvency Ratio | -1.26 | -4.17 | -3.86 | -1.47 | -0.60 |
| Operating Cash Flow Ratio | -1.21 | -5.37 | -4.25 | -2.75 | -1.24 |
| Short-Term Operating Cash Flow Coverage | -209.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 580.34M | $ 624.77M | $ 504.41M | $ 331.94M | $ 171.16M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.02 | 0.00 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.03 | 0.02 | 0.00 | 0.01 | 0.02 |
| Debt-to-Capital Ratio | 0.03 | 0.02 | 0.00 | 0.01 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.08 | 1.06 | 1.05 | 1.11 | 1.26 |
| Debt Service Coverage Ratio | -456.40 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.32 | 0.23 | 0.05 | 0.08 | 0.15 |
| Net Debt to EBITDA | 0.55 | 0.24 | 1.41 | 1.15 | 1.81 |
| Profitability Margins | |||||
| Gross Profit Margin | -43.89% | 45.23% | 82.86% | 95.87% | 93.83% |
| EBIT Margin | -72.84% | -3921.10% | -483.05% | -115.17% | -178.10% |
| EBITDA Margin | -70.74% | -3866.33% | -465.91% | -111.04% | -171.92% |
| Operating Profit Margin | -72.84% | -4671.07% | -574.85% | -122.72% | -179.91% |
| Pretax Profit Margin | -51.99% | -3921.10% | -483.05% | -115.17% | -178.10% |
| Net Profit Margin | -51.99% | -3921.10% | -483.05% | -115.17% | -178.10% |
| Continuous Operations Profit Margin | -51.99% | -3921.10% | -483.05% | -115.17% | -178.10% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 71.37% | 83.94% | 84.03% | 93.84% | 98.99% |
| Return on Assets (ROA) | -10.25% | -24.42% | -17.40% | -15.12% | -13.05% |
| Return on Equity (ROE) | -11.11% | -25.91% | -18.19% | -16.78% | -16.50% |
| Return on Capital Employed (ROCE) | -15.17% | -30.33% | -21.60% | -17.54% | -14.95% |
| Return on Invested Capital (ROIC) | -15.16% | -30.32% | -21.54% | -17.45% | -14.88% |
| Return on Tangible Assets | -10.25% | -24.42% | -17.40% | -15.12% | -13.05% |
| Earnings Yield | -3.72% | -13.08% | -5.52% | -7.79% | -5.97% |
| Efficiency Ratios | |||||
| Receivables Turnover | 36.62 | 2333.33 | 1299.17 | 241.38 | 25.33 |
| Payables Turnover | 17.90 | 0.25 | 0.61 | 0.49 | 0.82 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 6.99 | 0.25 | 2.78 | 5.66 | 3.23 |
| Asset Turnover | 0.20 | 0.01 | 0.04 | 0.13 | 0.07 |
| Working Capital Turnover Ratio | 0.35 | 0.01 | 0.06 | 0.19 | 0.12 |
| Cash Conversion Cycle | -10.43 | -1467.94 | -600.58 | -742.04 | -429.94 |
| Days of Sales Outstanding | 9.97 | 0.16 | 0.28 | 1.51 | 14.41 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 20.39 | 1468.09 | 600.87 | 743.55 | 444.35 |
| Operating Cycle | 9.97 | 0.16 | 0.28 | 1.51 | 14.41 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.80 | -3.03 | -2.00 | -2.10 | -1.58 |
| Free Cash Flow Per Share | -0.83 | -3.08 | -2.04 | -2.19 | -1.66 |
| Dividend Paid and CapEx Coverage Ratio | -30.02 | -64.19 | -48.66 | -25.32 | -21.10 |
| Capital Expenditure Coverage Ratio | -30.02 | -64.19 | -48.66 | -25.32 | -21.10 |
| Operating Cash Flow Coverage Ratio | -2.55 | -12.91 | -40.12 | -25.04 | -10.77 |
| Operating Cash Flow to Sales Ratio | -0.33 | -35.37 | -4.93 | -1.71 | -2.00 |
| Free Cash Flow Yield | -2.40% | -11.98% | -5.75% | -12.03% | -7.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -27.01 | -7.65 | -18.12 | -12.84 | -16.75 |
| Price-to-Sales (P/S) Ratio | 13.99 | 299.88 | 87.52 | 14.79 | 29.83 |
| Price-to-Book (P/B) Ratio | 2.99 | 1.98 | 3.30 | 2.15 | 2.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -41.64 | -8.35 | -17.40 | -8.31 | -14.26 |
| Price-to-Operating Cash Flow Ratio | -43.02 | -8.48 | -17.76 | -8.64 | -14.94 |
| Price-to-Earnings Growth (PEG) Ratio | 0.44 | -0.11 | -0.48 | -18.10 | -2.19 |
| Enterprise Value Multiple | -19.22 | -7.52 | -17.37 | -12.16 | -15.54 |
| Enterprise Value | 2.97B | 2.03B | 1.89B | 687.90M | 746.50M |
| EV to EBITDA | -19.22 | -7.52 | -17.37 | -12.16 | -15.54 |
| EV to Sales | 13.60 | 290.56 | 80.92 | 13.51 | 26.72 |
| EV to Free Cash Flow | -40.48 | -8.09 | -16.09 | -7.59 | -12.78 |
| EV to Operating Cash Flow | -41.83 | -8.22 | -16.42 | -7.89 | -13.38 |
| Tangible Book Value Per Share | 11.56 | 12.97 | 10.80 | 8.43 | 8.55 |
| Shareholders’ Equity Per Share | 11.56 | 12.97 | 10.80 | 8.43 | 8.55 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 2.47 | 0.09 | 0.41 | 1.23 | 0.79 |
| Net Income Per Share | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.71 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 1.44 | 42.10 | 5.54 | 1.76 | 2.08 |
| SG&A to Revenue | 0.29 | 5.07 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.21 | 4.96 | 0.79 | 0.23 | 0.29 |
| Income Quality | 0.63 | 0.90 | 1.02 | 1.49 | 1.12 |
Currency in USD
